Raúl Veiga Cabello

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Peter Nash, Bruce Kirkham, Masato Okada et al. · The Lancet · 2017 · 405 citations · Full text

Medicine, Immunology, Pharmacotherapy +13

Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study

Piotr Wiland, Sławomir Jeka, Eva Dokoupilová et al. · BioDrugs · 2020 · 38 citations · Full text

Medicine, Immunology, Pharmacology +17

Prevalence and clinical characteristics of patients with rheumatoid arthritis with interstitial lung disease using unstructured healthcare data and machine learning

Jose A Román Ivorra, Ernesto Trallero‐Araguás, María López‐Lasanta et al. · RMD Open · 2024 · 30 citations · Full text

Computing, Biomedical Informatics, Health Informatics +17

<b><i>RENACER</i></b> study: Assessment of 12-month efficacy and safety of 168 certolizumab PEGol rheumatoid arthritis-treated patients from a Spanish multicenter national database

Vicenç Torrente-Segarra, Ana Arana, Amalia Sanchez-Andrade Fernández et al. · Modern Rheumatology · 2015 · 14 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17